DOR BioPharma, Inc. Announces Collaboration With Numoda for the Execution of Confirmatory, Phase 3 Clinical Trial of orBec(R)

Published: Jun 30, 2008

EWING, NJ--(Marketwire - June 30, 2008) - DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Numoda Corporation (Numoda), experts in rapid information turnaround, for the execution of its upcoming confirmatory, Phase 3 clinical trial of orBecĀ® for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD).

Back to news